13744-81-5

Basic information

• Product Name: Benzenamine, 2,6-dinitro-N-phenyl-
• CAS NO: 13744-81-5
• Molecular Formula: C12H9N3O4
• Molecular Weight: 259.221
• Mol File: 13744-81-5.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: Benzenamine, 2,6-dinitro-N-phenyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenamine, 2,6-dinitro-N-phenyl-(13744-81-5)
• EPA Substance Registry System: Benzenamine, 2,6-dinitro-N-phenyl-(13744-81-5)

Safety Data

• Hazardous Substances Data: 13744-81-5(Hazardous Substances Data)

Upstream product

• 606-21-3 1-chloro-2,6-dinitrobenzene 
• 62-53-3 aniline 
• 609-73-4 o-nitroiodobenzene 
• 88-73-3 2-Chloronitrobenzene 
• 98-95-3 nitrobenzene 
• 26516-42-7 1-iodo-2,6-dinitrobenzene 
• 603-13-4 1,2,3-trinitrobenzene 
• 91-22-5 quinoline 
• 7221-24-1 4-anilino-3,5-dinitro-benzoic acid 

Downstream Products

• 56042-38-7 N-methyl-2,6-dinitrodiphenylamine 
• 565430-63-9 7-nitro-1-phenyl-1H-1,2,3-benzotriazole 
• 860766-50-3 3-nitro-N²-phenyl-o-phenylenediamine 

Relevant articles and documents

Design and Synthesis of Benzimidazoles As Novel Corticotropin-Releasing Factor 1 Receptor Antagonists

Benzazole derivatives with a flexible aryl group bonded through a one-atom linker as a new scaffold for a corticotropin-releasing factor 1 (CRF1) receptor antagonist were designed, synthesized, and evaluated. We expected that structural diversity could be expanded beyond that of reported CRF1 receptor antagonists. In a structure-activity relationship study, 4-chloro-N2-(4-chloro-2-methoxy-6-methylphenyl)-1-methyl-N7,N7-dipropyl-1H-benzimidazole-2,7-diamine 29g had the most potent binding activity against a human CRF1 receptor and the antagonistic activity (IC50 = 9.5 and 88 nM, respectively) without concerns regarding cytotoxicity at 30 μM. Potent CRF1 receptor-binding activity in brain in an ex vivo test and suppression of stress-induced activation of the hypothalamus-pituitary-adrenocortical (HPA) axis were also observed at 138 μmol/kg of compound 29g after oral administration in mice. Thus, the newly designed benzimidazole 29g showed in vivo CRF1 receptor antagonistic activity and good brain penetration, indicating that it is a promising lead for CRF1 receptor antagonist drug discovery research.